Newsletter Tool

PM Tracker

Today’s Big News

Jun 16, 2025

Big Pharma's 10 highest-paid CEOs of 2024

Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients

FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision

Former CEO Anne Wojcicki prevails in 23andMe auction, with final $305M bid

Biogen leads Cannes Lions Pharma shortlist, with BMS, Novartis cracking Health & Wellness category

Supernus acquires struggling Sage for $561M, taking a flier on depression drug Zurzuvae

Featured

Big Pharma's 10 highest-paid CEOs of 2024

By Fraiser Kansteiner,Zoey Becker,Eric Sagonowsky,Angus Liu,Kevin Dunleavy

The pay packages handed out for last year’s work seem to further cement a new status quo in the realm of CEO compensation, as several recently appointed pharma leaders settle into their roles and companies establish their market positions heading into the second half of the decade.

Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients

By Angus Liu

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy gene therapy’s safety profile.

FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision

By James Waldron

KalVista Pharmaceuticals has become the latest biotech to face delays to the FDA’s decision-making, as the agency blames a “heavy workload” for pushing back a PDUFA date.

Former CEO Anne Wojcicki prevails in 23andMe auction, with final $305M bid

By Conor Hale

Her $305 million offer topped the previous frontrunner, Regeneron, which bid $256 million last month and planned to incorporate the DNA company’s assets in its R&D.

Biogen leads Cannes Lions Pharma shortlist, with BMS, Novartis cracking Health & Wellness category

By Nick Paul Taylor

Biogen has emerged as a front-runner at the Cannes Lions International Festival of Creativity, snagging four spots on the Pharma shortlist for its work on Friedreich’s ataxia. But the biotech was absent from the Health & Wellness category, where Bristol Myers Squibb and Novartis led pharma representation.

Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae

By Kevin Dunleavy

Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, for $561 million up front, with the hope that it can help transform a newly launched treatment for postpartum depression into the indication's standard of care.

Gilead lays off 36 people after axing California expansion plan

By Nick Paul Taylor

Gilead is laying off 36 people as part of the rethink that saw it scrap plans to expand a biologics facility in California.

Eli Lilly's phase 1 amylin data impress analysts, pairing 11% weight loss with tolerable profile

By Nick Paul Taylor

Eli Lilly has shared phase 1 data on amylin analog eloralintide, impressing analysts with results that point to the potential for the drug candidate to form part of a market-leading Zepbound combination.